Back to top
more

Revance Therapeutics (RVNC)

(Delayed Data from NSDQ)

$3.95 USD

3.95
1,370,545

+0.18 (4.77%)

Updated May 3, 2024 04:00 PM ET

After-Market: $3.90 -0.05 (-1.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Revance (RVNC) Gets FDA Nod for Anti-Wrinkle Product, Stock Up

by Zacks Equity Research

FDA approves Revance Therapeutics' (RVNC) Daxxify as a long-acting neuromodulator with a strong label that includes 36-week efficacy data from the SAKURA clinical program.

Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 3.30% and 2.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines (BPMC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -20.18% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -3.30% and 7.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Twist Bioscience (TWST) delivered earnings and revenue surprises of 1.59% and 5.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 8.7% Jump Turn into More Strength?

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 4.35% and -1.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Revance Therapeutics (RVNC) Ahead of Earnings?

by Zacks Equity Research

Revance Therapeutics (RVNC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 6.14% and 12.73%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Revance Therapeutics, Inc. (RVNC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 9.24% and 6.89%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Revance Therapeutics, Inc. (RVNC) Q1 Earnings Expected to Decline

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 5.4% Jump Turn into More Strength?

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed

by Zacks Equity Research

Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.

Is a Surprise Coming for Revance (RVNC) This Earnings Season?

by Zacks Equity Research

Revance (RVNC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Revance Therapeutics (RVNC) Surges: Stock Moves 5.5% Higher

by Zacks Equity Research

Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

AbbVie's (ABBV) sBLA for Botox Gets Acceptance From FDA

by Zacks Equity Research

AbbVie's (ABBV) sBLA for expanding the label of Botox for use in pediatric patients with neurogenic detrusor overactivity gets acceptance from the FDA.

Revance's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Revance Therapeutics.

How Revance (RVNC) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Revance (RVNC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Implied Volatility Surging for Revance Therapeutics (RVNC) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Revance Therapeutics (RVNC) stock based on the movements in the options market lately.

Will Revance Therapeutics Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Revance Therapeutics.

Kinjel Shah headshot

Allergan (AGN) Shareholders Approve Acquisition by AbbVie

by Kinjel Shah

Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.

Will Revance Therapeutics (RVNC) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.